List of Excipients in Branded Drug LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

Generic Drugs Containing LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

Company	Ingredient	NDC	Excipient
AvKARE	losartan potassium and hydrochlorothiazide	42291-502	ALUMINUM OXIDE
AvKARE	losartan potassium and hydrochlorothiazide	42291-502	CARNAUBA WAX
AvKARE	losartan potassium and hydrochlorothiazide	42291-502	CELLULOSE, MICROCRYSTALLINE
AvKARE	losartan potassium and hydrochlorothiazide	42291-502	D&C YELLOW NO. 10
AvKARE	losartan potassium and hydrochlorothiazide	42291-502	HYDROXYPROPYL CELLULOSE
AvKARE	losartan potassium and hydrochlorothiazide	42291-502	HYPROMELLOSES
AvKARE	losartan potassium and hydrochlorothiazide	42291-502	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE?

# Of NDCs	Excipient
11	ALUMINUM OXIDE
14	CARNAUBA WAX
14	CELLULOSE, MICROCRYSTALLINE
11	D&C YELLOW NO. 10
14	HYDROXYPROPYL CELLULOSE
10	HYPROMELLOSE
4	HYPROMELLOSES

Excipient Strategy and Commercial Opportunities for Losartan Potassium and Hydrochlorothiazide

Last updated: August 13, 2026

Losartan potassium/hydrochlorothiazide is a mature, generic fixed-dose combination with limited composition-of-matter protection and substantial global price pressure. Commercial value now depends on manufacturing efficiency, product differentiation, supply reliability, dose flexibility, patient adherence, and regulatory execution. The strongest excipient opportunities are low-cost improvements in blend uniformity, hydrochlorothiazide dissolution, tablet robustness, moisture control, film coating, and differentiated dosage forms.

What is the commercial status of losartan potassium and hydrochlorothiazide?

Losartan potassium/hydrochlorothiazide is an oral angiotensin II receptor blocker and thiazide diuretic combination marketed in the United States under the brand name Hyzaar and by multiple generic manufacturers.

The principal approved strengths are:

Strength	Losartan potassium	Hydrochlorothiazide	Typical use
50 mg/12.5 mg	50 mg	12.5 mg	Initial or low-dose combination therapy
100 mg/12.5 mg	100 mg	12.5 mg	Escalated angiotensin blockade
100 mg/25 mg	100 mg	25 mg	Higher diuretic dose

The product is administered once daily for hypertension. The combination is commercially mature, with broad generic availability in the United States, Europe, India, Latin America, and other regulated and semi-regulated markets. Generic competition has reduced pricing, but the product remains attractive because hypertension is a high-volume chronic indication and the tablet is inexpensive to manufacture.

The commercial opportunity is strongest in the following areas:

1. Reliable low-cost supply in high-volume markets.
2. Differentiated 50/12.5 mg and 100/12.5 mg products for adherence.
3. Manufacturing platforms that reduce dissolution and content-uniformity risk.
4. Pediatric and geriatric dosage-form development.
5. Region-specific products with improved humidity and packaging performance.
6. Contract development and manufacturing for emerging-market suppliers.

What excipients are used in losartan potassium/hydrochlorothiazide tablets?

Reference-product formulations generally use conventional direct-compression or wet-granulation excipients. Exact composition varies by manufacturer and strength. Common excipient classes include:

Functional role	Candidate excipients	Commercial purpose
Diluent	Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate	Tablet mass, compressibility, cost control
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Granule strength and tablet integrity
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Rapid tablet breakup and dissolution
Glidant	Colloidal silicon dioxide	Flow improvement and reduced weight variation
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection force reduction
Moisture-control excipient	Mannitol, anhydrous lactose, low-moisture cellulose grades	Stability and packaging performance
Film former	Hypromellose, polyvinyl alcohol	Protection, identification, swallowability
Plasticizer	Polyethylene glycol, propylene glycol	Film flexibility
Opacifier or colorant	Titanium dioxide, iron oxides, approved lake colors	Product identification and light protection
Surfactant or wetting aid	Polysorbates, sodium lauryl sulfate	Possible dissolution support for hydrochlorothiazide

Losartan potassium is generally more soluble than hydrochlorothiazide, making hydrochlorothiazide the principal dissolution-risk component. The formulation must also maintain low-dose blend uniformity because 12.5 mg hydrochlorothiazide represents a relatively small fraction of total tablet mass.

The marketed Hyzaar label identifies conventional tablet excipients and confirms that the product is an immediate-release oral tablet. Product-specific excipient composition should be assessed from the applicable FDA label, DailyMed entry, and approved application records rather than inferred from another manufacturer’s formulation (U.S. Food and Drug Administration, 2024a; National Library of Medicine, 2024).

Which excipient strategy is most suitable for the combination?

A robust commercial formulation should prioritize simple, globally available excipients and a manufacturing process that tolerates normal variation in raw-material properties.

Direct compression strategy

Direct compression can offer the lowest cost and shortest process cycle. A typical platform would combine:

• Microcrystalline cellulose or spray-dried lactose as the primary diluent.
• Croscarmellose sodium or crospovidone as the disintegrant.
• Colloidal silicon dioxide as the glidant.
• Magnesium stearate or sodium stearyl fumarate as the lubricant.
• Hypromellose or polyvinyl alcohol for film coating.

This approach is attractive where the active pharmaceutical ingredients have suitable flow and compactibility. The primary risks are segregation, poor blend uniformity, lubricant overmixing, and variability in hydrochlorothiazide dissolution.

Wet-granulation strategy

Wet granulation is more expensive but can improve:

• Content uniformity.
• Flow properties.
• Tablet tensile strength.
• Control of segregation between losartan potassium and hydrochlorothiazide.
• Performance on high-speed tablet presses.

Povidone, copovidone, or pregelatinized starch can provide binder functionality. The process must control water exposure because losartan potassium and excipient moisture levels can affect granule behavior, assay, impurity formation, and dissolution.

Wet granulation is most defensible when a product has repeated scale-up failures, weight variation, capping, friability, or dissolution variability under direct compression.

Dry granulation strategy

Roller compaction is a practical intermediate option. It avoids substantial water exposure and can improve flow without the full cost and processing burden of wet granulation. The principal risks are overcompaction, reduced tablet porosity, slower disintegration, and altered hydrochlorothiazide dissolution.

A dry-granulation platform is commercially relevant for plants seeking high throughput and reduced solvent or water use.

What formulation problems create the largest commercial opportunity?

Hydrochlorothiazide dissolution

Hydrochlorothiazide has lower aqueous solubility than losartan potassium. Dissolution can be influenced by particle size, polymorphic form, wetting, compression force, disintegrant selection, and hydrophobic lubricant exposure.

Potential formulation responses include:

• Fine-particle hydrochlorothiazide with controlled particle-size distribution.
• Crospovidone or croscarmellose sodium to accelerate tablet breakup.
• Sodium lauryl sulfate or another suitable wetting aid, subject to tolerability and regulatory justification.
• Porous fillers that improve liquid penetration.
• Lower magnesium stearate concentration and controlled lubrication time.
• Separate granulation or ordered mixing to improve distribution of hydrochlorothiazide.

These approaches can improve dissolution without creating a complex drug-delivery system.

Blend uniformity

The 12.5 mg hydrochlorothiazide strengths present the greatest content-uniformity challenge. Relevant controls include:

• Narrow active-particle-size distributions.
• Geometric dilution or ordered mixing.
• Co-processed excipients.
• Segregation-resistant granulation.
• In-process near-infrared monitoring.
• Validated hold-time controls.

A supplier that can demonstrate consistent low-dose uniformity across commercial batch sizes may obtain a meaningful manufacturing advantage even where the finished product is therapeutically undifferentiated.

Tablet robustness

Large, high-dose combination tablets can experience capping, lamination, friability, and poor ejection. Microcrystalline cellulose, dibasic calcium phosphate, pregelatinized starch, and appropriate binder systems can improve mechanical strength.

The formulation should be optimized against:

• Tensile strength.
• Disintegration time.
• Dissolution profile.
• Compression speed.
• Ejection force.
• Packaging-related moisture exposure.

A high-strength tablet that remains robust at commercial press speeds can reduce manufacturing cost and batch failure risk.

Moisture and chemical stability

Losartan products have a history of regulatory scrutiny related to nitrosamine contamination across the broader sartans class. Losartan potassium manufacturing, excipient selection, water quality, process conditions, packaging, and supplier controls must be evaluated under current nitrosamine risk-management expectations (U.S. Food and Drug Administration, 2024b).

Excipient strategy should include:

• Low-nitrite excipient sourcing where relevant.
• Supplier qualification for lactose, cellulose, povidone, and coating systems.
• Control of water activity.
• Moisture-barrier blister or high-density polyethylene packaging.
• Stability testing under ICH conditions.
• Defined control strategies for degradation products and process impurities.

The opportunity is not a premium excipient alone. It is an integrated raw-material and process-control package that reduces recall and supply-interruption risk.

What formulations are protected or differentiated by excipients?

The original fixed-dose combination is not commercially protected by a strong, practical composition-of-matter estate in the United States. The relevant opportunity is formulation differentiation rather than basic exclusivity.

Potentially protectable or commercially differentiated concepts include:

• Modified-release or chronotherapeutic delivery.
• Orally disintegrating tablets.
• Multiparticulate or sprinkle formulations.
• Pediatric liquid or dispersible dosage forms.
• Bilayer tablets separating losartan potassium and hydrochlorothiazide.
• Taste-masked pediatric formulations.
• Moisture-resistant coating systems.
• Specific excipient ratios linked to dissolution or stability.
• Manufacturing processes that reduce segregation or impurities.
• Combination products with additional antihypertensive agents.

A formulation patent must provide more than a conventional substitution of one widely used diluent for another. Stronger claims generally require a defined composition, measurable performance, and a credible technical effect. For a mature generic product, formulation claims are more likely to support a niche product, licensing position, or regulatory differentiation than a broad market monopoly.

When did losartan potassium/hydrochlorothiazide lose exclusivity?

The key U.S. exclusivity and patent events occurred years ago.

Event	Approximate timing	Commercial impact
Cozaar approval	1995	Originator launch
Hyzaar approval	1995	Fixed-dose combination launch
Losartan composition patent protection	Expired around 2010	Opened broad generic entry
Combination-product patent protection	Expired in the early-to-mid 2010s	Removed major U.S. barriers to combination generics
Current market	Mature generic	Price and supply competition dominate

The exact legal status of individual patent records depends on jurisdiction, patent-term adjustment, pediatric extensions, terminal disclaimers, and listed patents. The relevant U.S. commercial position is clear: losartan potassium/hydrochlorothiazide is no longer an originator-protected growth product.

What is the Orange Book status of losartan potassium/hydrochlorothiazide?

The FDA Orange Book is the controlling source for current U.S. reference-listed-drug, patent-listing, and exclusivity information. Hyzaar has historically been listed as the reference product for losartan potassium and hydrochlorothiazide tablets. The product is approved through the abbreviated new drug application pathway by multiple manufacturers.

For a current launch assessment, the commercially important questions are:

• Whether any patent remains listed against the applicable strength.
• Whether a listed patent carries a current expiration date.
• Whether the applicant must make a Paragraph IV certification.
• Whether 30-month litigation-related stays apply.
• Whether the proposed product has a different dosage form or labeling that changes the regulatory pathway.

Because the product is mature, a new applicant is more likely to face ordinary ANDA technical and commercial barriers than a strong originator patent block. FDA Orange Book records should be reviewed by strength and dosage form before filing or acquisition analysis (U.S. Food and Drug Administration, 2024c).

Are Paragraph IV challenges still relevant?

Paragraph IV activity is less central than it was during the original generic-entry period. For a new conventional immediate-release tablet, the practical issue is usually whether any unexpired listed patent remains relevant to the proposed ANDA.

A Paragraph IV strategy could still matter if:

• A patent covers an unexpired formulation or manufacturing process.
• The applicant seeks an early market position.
• The proposed product avoids an unexpired method-of-use claim.
• A niche formulation has later-issued patents.
• A patent owner asserts a listed claim after filing.

For a conventional losartan potassium/hydrochlorothiazide tablet using established excipients, technical bioequivalence, manufacturing scale-up, supply economics, and product selection are generally more important than Paragraph IV litigation.

What patent litigation and settlement agreements affect the product?

The central historical disputes involved the original losartan and Hyzaar patent estate and generic entry timing. Those disputes have largely lost commercial significance because the core exclusivity periods expired.

Current risk is more likely to arise from:

• Later formulation patents.
• Process patents.
• Trade-secret claims involving manufacturing.
• Supplier agreements and technology licenses.
• Labeling disputes.
• Patent claims directed to new combination strengths or delivery systems.

Settlement agreements from the original generic-entry period may have included delayed-entry terms, authorized-generic arrangements, or other commercial provisions. Their economic impact is generally historical for a new entrant unless a later agreement imposes an enforceable restriction on a particular market or licensee. Public patent and court records should be reviewed for any product-specific continuing obligation before a transaction closes.

How does losartan potassium/hydrochlorothiazide compare with competing antihypertensive combinations?

Product class	Example	Excipient and formulation opportunity	Competitive position
ARB/thiazide	Losartan/HCTZ	Low-cost immediate-release, stability, adherence	Mature and price-sensitive
ARB/CCB	Losartan/amlodipine or similar combinations	Dissolution and dose flexibility	Strong chronic-use competition
ACE inhibitor/thiazide	Lisinopril/HCTZ	Standard tablet platforms	High generic competition
ARB/thiazide	Valsartan/HCTZ	Similar manufacturing economics	Strong therapeutic substitute
ARB/thiazide	Irbesartan/HCTZ	Generic and regional competition	Differentiation depends on supply and price
Triple antihypertensive	ARB/CCB/thiazide	Bilayer, trilayer, or advanced compression	Higher formulation complexity and potential value

Losartan/HCTZ can compete effectively when priced below newer combinations, supplied consistently, and offered in strengths aligned with prescribing patterns. It is less attractive as a premium product unless the manufacturer can demonstrate an adherence, pediatric, stability, or manufacturing advantage.

What generic launch scenarios exist?

Standard ANDA launch

This is the lowest-risk route for a conventional immediate-release tablet. The product requires pharmaceutical equivalence, bioequivalence, validated manufacturing, stability data, and compliant labeling.

Authorized or licensed generic

A licensed product can use an established formulation and manufacturing package, reducing development time. The economics depend on transfer fees, supply commitments, and territory.

Differentiated formulation

An orally disintegrating, dispersible, pediatric, or bilayer product may create a smaller but less commoditized market. Regulatory requirements and clinical bridging become more complex.

Regional low-cost launch

Emerging markets may reward flexible packaging, local sourcing, and simplified manufacturing more than formulation innovation. The principal barriers are registration, procurement access, pharmacovigilance, and reliable active-ingredient supply.

Contract manufacturing platform

A manufacturer with a validated high-throughput process can supply multiple labels and markets. This model monetizes process capability rather than brand differentiation.

What manufacturing and intellectual-property barriers remain?

The main barriers are operational rather than foundational patent barriers.

Manufacturing barriers

• Low-dose hydrochlorothiazide uniformity.
• Segregation during transfer and compression.
• Dissolution failure after scale-up.
• Lubrication sensitivity.
• Moisture-related stability changes.
• Coating defects.
• Nitrosamine risk management.
• Variation in API particle size and polymorphic form.
• Packaging performance in hot and humid climates.

Intellectual-property barriers

• Later-issued formulation patents.
• Process patents with narrow but commercially relevant claims.
• Trade secrets involving granulation, blending, or coating.
• Proprietary co-processed excipients.
• Device or packaging claims for differentiated dosage forms.
• Method-of-use claims linked to a newly approved indication.

A conventional formulation using standard excipients is unlikely to support meaningful exclusion by itself. A process that consistently produces a superior dissolution profile, lower impurity burden, or improved stability may support narrower patent claims and a stronger licensing proposition.

What licensing opportunities exist?

Licensing opportunities are most credible in four categories:

1. Formulation technology. A developer can license a dispersible, orally disintegrating, pediatric, or bilayer platform.
2. Manufacturing technology. Roller compaction, continuous manufacturing, process analytical technology, or segregation-control systems can be licensed to generic producers.
3. Excipient systems. Co-processed fillers, superdisintegrant systems, or low-moisture platforms can be supplied under a formulation or technology agreement.
4. Regional commercialization. A dossier owner can license local marketing rights where procurement networks and registration capability create value.

The commercial diligence focus should be freedom to operate, ownership of formulation data, regulatory transferability, API compatibility, minimum-volume commitments, and the ability to use the technology across strengths and jurisdictions.

What revenue exposure exists for manufacturers?

Losartan/HCTZ revenue is exposed to generic price erosion, tender concentration, wholesaler inventory cycles, API disruptions, and recall risk. The product can still produce attractive cash flow when manufacturing cost is low and the portfolio includes multiple strengths and markets.

Revenue resilience improves when a manufacturer has:

• More than one qualified API source.
• Both 50/12.5 mg and 100/12.5 mg strengths.
• Regional packaging capability.
• Multiple regulatory approvals.
• Stable institutional and retail channels.
• A broader ARB and cardiovascular portfolio.
• Differentiated formulations that avoid direct tender-only competition.

A premium price is difficult to sustain for an ordinary immediate-release tablet. The stronger business case is a high-volume, low-cost platform with disciplined quality controls.

How strong is the patent estate for losartan potassium/hydrochlorothiazide?

The core patent estate is weak for blocking a conventional generic product in the United States because the principal compound and combination exclusivity periods have expired. Patent strength is higher only for narrowly defined later innovations.

Patent category	Current strategic strength
Losartan composition of matter	Low
Hydrochlorothiazide composition of matter	Negligible
Original fixed-dose combination	Low
Conventional immediate-release tablet	Low
Novel pediatric or dispersible formulation	Potentially moderate
Modified-release delivery	Potentially moderate to strong if technically credible
Manufacturing process	Narrow, fact-dependent
Nitrosamine-control process	Potentially useful, but claim scope must be carefully assessed
Packaging or stability system	Usually narrow and commercially specific

Geographic coverage varies. European, U.S., Japanese, Indian, and other national patent positions must be evaluated separately because filing dates, patent-term rules, supplementary protection rights, and litigation outcomes differ.

Key Takeaways

• Losartan potassium/hydrochlorothiazide is a mature generic fixed-dose combination with limited core patent protection.
• The main formulation challenge is hydrochlorothiazide dissolution combined with low-dose blend uniformity.
• Direct compression offers the lowest cost; wet or dry granulation may provide better process robustness.
• The most valuable excipient work focuses on disintegration, wetting, flow, compaction, moisture control, and lubricant optimization.
• Nitrosamine risk management is a material quality and supply-chain issue for losartan products.
• Conventional tablets are unlikely to command a premium without a measurable technical or regulatory advantage.
• Pediatric, orally disintegrating, dispersible, bilayer, and stability-enhanced products offer the clearest formulation-led opportunities.
• Current commercial barriers are manufacturing reliability, regulatory execution, API sourcing, and price competition rather than the original Hyzaar patent estate.
• Licensing value is strongest in formulation platforms, process technology, regional dossiers, and contract manufacturing.

FAQs

Can hydrochlorothiazide be replaced with another diuretic in the same formulation?

Yes, but the product would be a different fixed-dose combination requiring a separate regulatory strategy, new bioequivalence or clinical justification, and a distinct patent and labeling analysis.

Is an orally disintegrating losartan/HCTZ tablet commercially attractive?

It can be attractive for patients with swallowing difficulties and for adherence-focused portfolios. The opportunity is constrained by hydrochlorothiazide taste, moisture sensitivity, tablet friability, and the need to demonstrate rapid dispersion without compromising dissolution.

Which excipient is most important for losartan/HCTZ dissolution?

No single excipient controls performance across all formulations. Croscarmellose sodium, crospovidone, wetting agents, porous fillers, particle-size control, and limited lubricant exposure are usually evaluated together.

Does the product require a biosimilar strategy?

No. Losartan potassium and hydrochlorothiazide are chemically synthesized small molecules. The relevant pathway is an ANDA or another small-molecule regulatory pathway, not a biosimilar application.

Can a manufacturer patent a new losartan/HCTZ formulation?

Yes, if the formulation satisfies patentability requirements and demonstrates a sufficiently specific and non-obvious technical contribution. A routine excipient substitution without unexpected performance is unlikely to provide strong protection.

References

1. National Library of Medicine. (2024). DailyMed: Hyzaar, losartan potassium and hydrochlorothiazide tablet, film coated. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2024a). Hyzaar prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024b). Control of nitrosamine impurities in human drugs: Guidance for industry. FDA.

4. U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

5. U.S. Food and Drug Administration. (1995). Approval history and labeling for Cozaar and Hyzaar. FDA.